Guardion Health Sciences Income Statement 2023-2011 | GHSI

Brief overview of income trends at Guardion Health Sciences

The conclusions below are based on five years of reported results. Guardion Health Sciences reported revenue of $942 thousand in 2018 and $12.2 million by 2023. Overall revenue changed by +1200.1%, equal to an annualized rate of about 67%. The annual growth rate indicates an exceptionally strong top-line trend.

At the gross-profit level, the result moved from 544 thousand dollars to 5.4 million dollars, a change of +891.7%. Costs absorbed a larger share of revenue over the period. The gross margin was 57.7% at the start and 44% at the end. The margin decline reflects a less favorable sales-and-cost structure.

Over the period, EBITDA shifted from −$6.1 million to −$4.3 million, a change of +28.8%. EBITDA lagged revenue, showing weaker operating momentum. Comparing the endpoints gives EBITDA margins of −643.5% and −35.2%. The increased EBITDA share is a positive sign.

Across the five years, the net result shifted from −$7.8 million to $158 thousand. The trajectory reversed from a loss to positive earnings.

Conclusion

The five-year picture requires weighing both strengths and weaknesses. Key strengths include revenue expansion, higher operating efficiency and net-income growth. The weaker side of the profile includes weaker gross profitability and limited operating profitability. Investors should continue to monitor margins, costs, and earnings quality.